Pliant Therapeutics (PLRX) News Today $1.33 -0.04 (-2.92%) Closing price 04:00 PM EasternExtended Trading$1.34 +0.01 (+0.75%) As of 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PLRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceMay 21 at 5:51 PM | finance.yahoo.comPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceMay 21 at 4:03 PM | globenewswire.comDeutsche Bank AG Buys 1,017,500 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)Deutsche Bank AG increased its stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 66.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,551,865 shares of the company's stock after purchasing an additional 1,May 16, 2025 | marketbeat.comGranahan Investment Management LLC Has $6.94 Million Stock Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX)Granahan Investment Management LLC reduced its holdings in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 28.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 527,147 shares of the company's stock afMay 12, 2025 | marketbeat.comPliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comBarclays PLC Lowers Stock Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX)Barclays PLC cut its stake in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 75.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 101,823 shares of the company's stock after selling 319,676 shaMay 6, 2025 | marketbeat.comPliant Therapeutics announces workforce reductionMay 3, 2025 | uk.investing.comPliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical TrialsMay 3, 2025 | nasdaq.comBay Area biotech company Pliant Therapeutics slashes staff after losing $655 million in valueMay 2, 2025 | msn.comPliant Therapeutics Announces Strategic Realignment of Workforce and OperationsMay 1, 2025 | globenewswire.com649,660 Shares in Pliant Therapeutics, Inc. (NASDAQ:PLRX) Purchased by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. purchased a new position in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 649,660 shares of the company's stock, valued atMay 1, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Sells 200,327 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)Price T Rowe Associates Inc. MD reduced its position in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 4.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,634,486 shares of the company's sMay 1, 2025 | marketbeat.comFirst Light Asset Management LLC Has $22.14 Million Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)First Light Asset Management LLC reduced its stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 34.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,681,110 shares of the company's stock aftApril 30, 2025 | marketbeat.comPliant Therapeutics (PLRX) to Release Quarterly Earnings on MondayPliant Therapeutics (NASDAQ:PLRX) will be releasing its Q1 2025 earnings before the market opens on Monday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-5-pliant-therapeutics-inc-stock/)April 30, 2025 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Hold" by BrokeragesShares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) have been given a consensus rating of "Hold" by the twelve brokerages that are presently covering the firm, Marketbeat Ratings reports. Twelve equities research analysts have rated the stock with a hold rating. The average 1 yearApril 28, 2025 | marketbeat.comBlue Owl Capital Holdings LP Has $36.47 Million Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)Blue Owl Capital Holdings LP reduced its holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 7.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,769,199 shares of the company's stock after selling 235,000 shares during tApril 26, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRXApril 25, 2025 | globenewswire.comSilverarc Capital Management LLC Makes New $17.33 Million Investment in Pliant Therapeutics, Inc. (NASDAQ:PLRX)Silverarc Capital Management LLC bought a new stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 1,315,601 shares of the company's stock, valued at approximApril 24, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRXApril 21, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRXApril 21, 2025 | globenewswire.comVanguard Group Inc. Has $42.52 Million Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX)Vanguard Group Inc. reduced its holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 8.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,228,755 shares of the company's stock after seApril 14, 2025 | marketbeat.comPliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International ConferenceApril 7, 2025 | globenewswire.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Sees Significant Growth in Short InterestPliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 3,980,000 shares, an increase of 21.0% from the February 28th total of 3,290,000 shares. Approximately 7.0% of the company's shares are sold short. Based on an average daily volume of 2,470,000 shares, the days-to-cover ratio is currently 1.6 days.April 4, 2025 | marketbeat.comPliant Therapeutics: An Activist On DeckApril 3, 2025 | seekingalpha.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 28, 2025 | prnewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRXMarch 26, 2025 | globenewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 23, 2025 | globenewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - PLRXMarch 21, 2025 | markets.businessinsider.comPliant Therapeutics (NASDAQ:PLRX) Receives Neutral Rating from HC WainwrightHC Wainwright reiterated a "neutral" rating on shares of Pliant Therapeutics in a research report on Tuesday.March 19, 2025 | marketbeat.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 19, 2025 | globenewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 18, 2025 | markets.businessinsider.comPliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor TypesMarch 18, 2025 | benzinga.comPliant Therapeutics announces interim Phase 1 data from PLN-101095March 17, 2025 | markets.businessinsider.comPliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid TumorsMarch 17, 2025 | globenewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 15, 2025 | globenewswire.comPliant Therapeutics, Inc.: Pliant Therapeutics Adopts Limited Duration Stockholder Rights AgreementMarch 13, 2025 | finanznachrichten.deSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 13, 2025 | prnewswire.comPliant Therapeutics Adopts Limited Duration Stockholder Rights AgreementMarch 13, 2025 | globenewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 9, 2025 | globenewswire.comHC Wainwright Issues Optimistic Estimate for PLRX EarningsPliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2025 EPS estimates for Pliant Therapeutics in a research note issued to investors on Tuesday, March 4th. HC Wainwright analyst E. Arce now anticipates that the company will postMarch 8, 2025 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Rating of "Hold" from AnalystsPliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) has received a consensus rating of "Hold" from the twelve analysts that are currently covering the company, MarketBeat Ratings reports. Twelve equities research analysts have rated the stock with a hold rating. The average 12 month price obMarch 8, 2025 | marketbeat.comEquities Analysts Offer Predictions for PLRX FY2029 EarningsPliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - Stock analysts at HC Wainwright upped their FY2029 EPS estimates for Pliant Therapeutics in a report released on Tuesday, March 4th. HC Wainwright analyst E. Arce now anticipates that the company will earn $1.80 per share for the year, up frMarch 7, 2025 | marketbeat.comCantor Fitzgerald Predicts PLRX FY2025 EarningsPliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Pliant Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Stavropoulos expeMarch 7, 2025 | marketbeat.comLeerink Partnrs Brokers Raise Earnings Estimates for PLRXPliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - Equities research analysts at Leerink Partnrs increased their Q1 2025 EPS estimates for Pliant Therapeutics in a research note issued to investors on Monday, March 3rd. Leerink Partnrs analyst F. Khurshid now anticipates that the company wilMarch 7, 2025 | marketbeat.comLeerink Partnrs Downgrades Pliant Therapeutics (NASDAQ:PLRX) to HoldLeerink Partnrs lowered shares of Pliant Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday.March 6, 2025 | marketbeat.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 5, 2025 | globenewswire.comCitigroup Has Lowered Expectations for Pliant Therapeutics (NASDAQ:PLRX) Stock PriceCitigroup reduced their price target on shares of Pliant Therapeutics from $4.00 to $1.50 and set a "neutral" rating on the stock in a research report on Tuesday.March 5, 2025 | marketbeat.comHC Wainwright Reaffirms Neutral Rating for Pliant Therapeutics (NASDAQ:PLRX)HC Wainwright reiterated a "neutral" rating on shares of Pliant Therapeutics in a report on Tuesday.March 5, 2025 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Given New $3.00 Price Target at Royal Bank of CanadaRoyal Bank of Canada lowered their price target on Pliant Therapeutics from $4.00 to $3.00 and set a "sector perform" rating for the company in a report on Tuesday.March 5, 2025 | marketbeat.comLeerink Partners Downgrades Pliant Therapeutics (PLRX)March 5, 2025 | msn.com Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address PLRX Media Mentions By Week PLRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PLRX News Sentiment▼1.770.65▲Average Medical News Sentiment PLRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PLRX Articles This Week▼14▲PLRX Articles Average Week Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CYRX News OLMA News ARCT News ITOS News PHAT News ATYR News TRDA News CGC News IMMP News AURA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PLRX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PLRX Stock Free PLRX Stock Alerts